Patients sought for clinical trial of rare blood disease

Patients with intermediate-1 or -2 or high-risk myelofibrosis are sought for a comparative clinical trial at George Washington University Medical Faculty Associates of Washington, D.C.

George Washington University Medical Faculty Associates and other hospitals across the U.S. are participating with a goal to enroll approximately 300 participants. The study is designed to evaluate a potential new treatment option for patients with myelofibrosis who have abnormally low platelet counts, also known as thrombocytopenia.

This is a randomized Phase 3 study that will evaluate investigational oral pacritinib versus Best Available Therapy in patients with thrombocytopenia and primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis.

Those eligible for the study must be 18 years of age or older and have intermediate-1 or -2 or high-risk myelofibrosis.

For more information and to see if you, or someone you know, may be eligible for the PERSIST-2 study, visit PERSISTProgram.com and answer a few quick questions, or visit clinicaltrials.gov and use Identifier NCT02055781.